Princeton-based Certara, the global model-informed drug development and decision support leader, reported on Tuesday it acquired a range of modeling and simulation technology assets from In Silico ...

In-silico bioequivalence approach using Simcyp’s Multi-Phase Multi-Layer Mechanistic Dermal Absorption model successfully replaced in-vivo, clinical studies in FDA ANDA approval PRINCETON, NJ – June ...

Pharmaceutical biosimulation software company Certara won an R&D 100 Award from R&D World magazine for its its Simcyp COVID-19 Vaccine Model. The nearly 50-year-old worldwide competition lists the top ...

Certara reported that its drug development software, including modeling and simulation services, supported 95% of the 20 novel drugs approved by the FDA in the first half of this year. The number ...

Certara, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, announced that it is partnering with Phase I Unit, ...

Certara will host a Phoenix® User Group Meeting and lead 15 presentations and poster sessions focusing on the newest applications of model-informed drug development PRINCETON, NJ – Nov. 1, 2018 – ...

RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered ...

PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global model-informed drug development and decision support leader, today reported that it has acquired a range of modeling and simulation technology ...

Certara, the global model-informed drug development and decision support leader, announced that its Simcyp Population-based Simulator was used to support Galderma’s successful US Food and Drug ...

PRINCETON, N.J.--(BUSINESS WIRE)--Certara ® the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that its Simcyp ® ...